Umckalor

Pharmacological properties

Umckalor contains an original extract from the roots of pelargonium (pelargonium sidoides). standardized phytoextract (eps 7630), which has no analogues *, combines the proven pronounced antiviral, antibacterial, anti-inflammatory and immunomodulatory effects, is effective at all stages of ARI etiopathogenesis, prevents the progression of diseases and the development of complications.

In the course of studies, after ingestion of the extract, inhibition of the course of the disease was noted.

In vitro tests have confirmed the following effects of Umckalor:

stimulation of non-specific defense mechanisms:

• stimulation of the frequency of contraction of the ciliated epithelium;
• modulation of the synthesis of interferon and pro-inflammatory cytokines;
• stimulation of cell activity - natural killer cells;
• phagocyte stimulation, expression of molecular adhesion, chemotaxis;

antimicrobial effects:

• moderate direct antibacterial and antiviral properties;
• growth / inhibition of adhesion of A-streptococci to desquamative / living epithelial cells;
• inhibition of β-lactamase;

cytoprotective properties:

• inhibition of human leukocyte elastase;
• antioxidant properties.

Pharmacokinetics The drug is a complex mixture of many components, which is generally regarded as an active substance. There is no data on the pharmacokinetics of the drug.

* NB! Umckalor has no analogues in Ukraine due to the fact that the EPs 7630 extract for the production of Umckalor is not sold to other manufacturers, so its characteristics cannot be repeated in other drugs (APTECA Weekly No. 7 (978) “Phytomedications: brands and their analogues - what unites and what is the difference? ”).

Indications

Acute and chronic infections of the respiratory tract and ENT organs (bronchitis, sinusitis, tonsillitis, rhinopharyngitis).

Application

Umckalor rr should be taken with a small amount of liquid 30 minutes before meals in the morning, afternoon and evening.

In the acute stage of the disease, usually prescribed:

• adults and children over the age of 12 years - 30 drops 3 times a day;
• children aged 6 to 12 years - 20 drops 3 times a day;
• children aged 1 year to 6 years - 10 drops 3 times a day.

For the prevention of relapse and further treatment of chronic diseases, adults and children over the age of 12 years are prescribed 10–20 drops 3 times a day.

The average duration of treatment for acute illness and relapse prevention is 7–10 days. The total duration of treatment should not exceed 3 weeks.

Hold the bottle vertically, if necessary, lightly tap on its bottom.

Umckalor Syrup

Adults and children over the age of 12 years - 7.5 ml of syrup 3 times a day.

Children aged 6-12 years - 5 ml of syrup 3 times a day.

Children aged 1 to 5 years - 2.5 ml of syrup 3 times a day.

Mode of application. The syrup should be taken orally 3 times a day in the morning, afternoon and evening.

Duration of treatment. After the symptoms disappear, it is recommended that treatment be continued for several days to prevent relapse.

The duration of treatment should not exceed 3 weeks.

Children. Umckalor syrup is not recommended for use in children under the age of 1 year due to insufficient data on its safety and effectiveness in the provided group of patients.

Umckalor tablets. Adults and children over the age of 12 years: 1 tablet 3 times a day (morning, afternoon and evening); children aged 6 to 12 years: 1 tablet 2 times a day (morning and evening). Umckalor is recommended to be taken without chewing, with a small amount of liquid.

In addition, in order to prevent recurrence of the disease, it is recommended to continue taking it for several more days after the disappearance of the symptoms of the disease. The average duration of treatment is 7-10 days. The duration of therapy should not exceed 3 weeks.

If, despite compliance with the prescribed dosage, no improvement is observed, the patient should inform the doctor about this.

Contraindications

Hypersensitivity to the components of the drug; increased tendency to bleeding, taking medications that slow down the process of blood coagulation; severe liver and kidney diseases (due to the lack of sufficient experience with the use of this drug in such cases).

Side effects

From the digestive system: digestive tract disorders (including stomach pain, heartburn, nausea, diarrhea), slight bleeding of the gums.

From the respiratory system: mild nosebleeds.

On the part of the skin / immune system: hypersensitivity reactions (including rash, urticaria, itching of the skin and mucous membrane). In isolated cases, severe hypersensitivity reactions with swelling of the face, shortness of breath and a decrease in blood pressure) are possible.

From the hepatobiliary system: increased liver function. A causal relationship between the increase in these indicators and the use of the drug has not been demonstrated.

special instructions

If the symptoms of the disease do not disappear within 1 week, elevated body temperature persists for more than 3 days or the general condition worsens, you should immediately consult a doctor.

Use during pregnancy and lactation. It is not recommended to take the drug during pregnancy and lactation due to insufficient clinical experience with its use in this group of patients.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. The effect on the reaction rate when driving vehicles or working with other mechanisms has not been studied, but it should be borne in mind that the drug contains 12 vol.% Ethanol.

Children. There is no experience with the use of the drug in children under the age of 1 year, therefore Umckalor is prescribed for children from 1 year. The use of the drug Umckalor for the treatment of young children (1 year to 6 years) is recommended under the supervision of a doctor.

The drug in the form of tablets is prescribed for children over the age of 6 years.

Interactions

There are still no reports of this.

Due to the possible effect of the drug Umckalor on the parameters of blood coagulation, it is possible that with simultaneous use it can affect the effect of indirect anticoagulants such as warfarin. When conducting a placebo-controlled double-blind clinical trial involving healthy volunteers, no interactions of Umckalor with penicillin V were detected.

Overdose

To date, no cases of overdose have been reported. amplification of adverse reactions is possible.

Storage conditions

Umckalor rr. at a temperature not exceeding 30 ° c.

Note. In extracts of plant origin in the form of solutions, clouding is possible over time, which does not affect the effectiveness of the drug. Since Umckalor is a herbal medicine, slight changes in its color and taste are possible.

Umckalor syrup. It does not require special storage conditions. After opening the bottle, the shelf life is 6 months.

Umckalor tablets. It does not require special storage conditions.

Exclusive Distributor: Naturfarm, ul. Lesnaya, 30a, Kiev, Pushcha-Voditsa, 04075; phone: (044) 401-81-03.

Supplier: Alpen Pharma AG (Switzerland).